Q2 2024 · 13F-HR
BVF INC/ILholdings as filed
Filed 2024-08-14 · accession 0000921895-24-001815
$3.57B
Reported value
60
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $956.4M | 26.8% | 21,751,284 | Common | SHARED |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $232.1M | 6.51% | 5,981,212 | Common | SHARED |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $154.1M | 4.32% | 5,161,801 | Common | SHARED |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $151.9M | 4.26% | 3,186,376 | Common | SHARED |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $149.4M | 4.19% | 4,370,024 | Common | SHARED |
| G3855L106 | GHRS | GH RESEARCH PLC | $121.3M | 3.40% | 10,400,158 | Common | SHARED |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $115.0M | 3.22% | 3,319,290 | Common | SHARED |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $100.3M | 2.81% | 5,750,683 | Common | SHARED |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $98.9M | 2.77% | 9,135,893 | Common | SHARED |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $97.7M | 2.74% | 2,487,762 | Common | SHARED |
| 98419J206 | XOMA | XOMA CORP DEL | $86.1M | 2.41% | 3,633,743 | Common | SHARED |
| 50127T109 | KURA | KURA ONCOLOGY INC | $84.0M | 2.36% | 4,082,037 | Common | SHARED |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $82.3M | 2.31% | 3,922,413 | Common | SHARED |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $76.9M | 2.15% | 955,000 | Common | SHARED |
| 156944100 | CGON | CG ONCOLOGY INC | $76.3M | 2.14% | 2,417,885 | Common | SHARED |
| N5749R100 | 2GH | MERUS N V | $75.7M | 2.12% | 1,279,049 | Common | SHARED |
| H00263105 | ACIU | AC IMMUNE SA | $75.2M | 2.11% | 18,834,936 | Common | SHARED |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $74.5M | 2.09% | 4,661,194 | Common | SHARED |
| 282559103 | ETNBGBP | 89BIO INC | $60.6M | 1.70% | 7,568,479 | Common | SHARED |
| 15102K100 | CELC | CELCUITY INC | $56.8M | 1.59% | 3,466,000 | Common | SHARED |
| 88427A107 | — | THIRD HARMONIC BIO INC | $56.8M | 1.59% | 4,365,933 | Common | SHARED |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $51.3M | 1.44% | 1,190,107 | Common | SHARED |
| 98985Y108 | ZYME | ZYMEWORKS INC | $50.0M | 1.40% | 5,870,000 | Common | SHARED |
| 29668H708 | EPIEUR | ESSA PHARMA INC | $46.0M | 1.29% | 8,748,629 | Common | SHARED |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $40.8M | 1.14% | 1,162,306 | Common | SHARED |
| 36315X101 | LKFT | GALAPAGOS NV | $38.9M | 1.09% | 1,569,422 | Common | SHARED |
| 03589W102 | ANNX | ANNEXON INC | $34.3M | 0.96% | 7,000,000 | Common | SHARED |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $34.1M | 0.96% | 10,333,600 | Common | SHARED |
| 344174107 | FHTX | FOGHORN THERAPEUTICS INC | $30.5M | 0.85% | 5,302,000 | Common | SHARED |
| 13124Q106 | — | CALLIDITAS THERAPEUTICS AB | $29.2M | 0.82% | 750,000 | Common | SHARED |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $29.2M | 0.82% | 1,521,948 | Common | SHARED |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $29.0M | 0.81% | 2,742,409 | Common | SHARED |
| 29286M105 | — | ENGENE HOLDINGS INC | $21.2M | 0.59% | 2,251,037 | Common | SHARED |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $18.5M | 0.52% | 441,528 | Common | SHARED |
| 89854M101 | TCRX | TSCAN THERAPEUTICS INC | $17.5M | 0.49% | 2,989,474 | Common | SHARED |
| 28617K101 | ELDN | ELEDON PHARMACEUTICALS INC | $16.6M | 0.47% | 6,293,282 | Common | SHARED |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $16.6M | 0.46% | 16,552,417 | Common | SHARED |
| 4525EP101 | VTLUSD | IMMUNIC INC | $9.9M | 0.28% | 8,902,972 | Common | SHARED |
| 45175G108 | — | IKENA ONCOLOGY INC | $7.9M | 0.22% | 4,769,164 | Common | SHARED |
| 92673K108 | VIGL | VIGIL NEUROSCIENCE INC | $7.3M | 0.20% | 1,813,633 | Common | SHARED |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $7.0M | 0.20% | 2,000,000 | Common | SHARED |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $6.4M | 0.18% | 5,228,461 | Common | SHARED |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $6.2M | 0.17% | 2,312,200 | Common | SHARED |
| 92337C203 | VSTM | VERASTEM INC | $5.0M | 0.14% | 1,685,219 | Common | SHARED |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $4.1M | 0.11% | 343,055 | Common | SHARED |
| 92539P101 | — | VERVE THERAPEUTICS INC | $3.2M | 0.09% | 650,000 | Common | SHARED |
| 60853G106 | MOLN | MOLECULAR PARTNERS AG | $3.2M | 0.09% | 443,221 | Common | SHARED |
| 690469101 | OVID | OVID THERAPEUTICS INC | $3.0M | 0.08% | 3,853,818 | Common | SHARED |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $2.8M | 0.08% | 917,826 | Common | SHARED |
| 38000Q102 | GLYCEUR | GLYCOMIMETICS INC | $2.7M | 0.08% | 9,544,262 | Common | SHARED |
| 720795202 | — | PIERIS PHARMACEUTICALS INC | $2.5M | 0.07% | 257,626 | Common | SHARED |
| 46124U107 | IVA | INVENTIVA SA | $2.0M | 0.06% | 686,040 | Common | SHARED |
| 92765F108 | RYI | VIRACTA THERAPEUTICS INC | $2.0M | 0.06% | 3,614,662 | Common | SHARED |
| 34962G109 | TOCAEUR | FORTE BIOSCIENCES INC | $1.6M | 0.04% | 2,982,105 | Common | SHARED |
| 29286M113 | — | ENGENE HOLDINGS INC | $1.3M | 0.04% | 945,402 | Common | SHARED |
| H57830103 | — | NLS PHARMACEUTICS LTD | $1.2M | 0.03% | 5,747,126 | Common | SHARED |
| 90466Y103 | — | UNICYCIVE THERAPEUTICS INC | $1.1M | 0.03% | 2,200,000 | Common | SHARED |
| 76200L309 | RZLT | REZOLUTE INC | $820,505 | 0.02% | 190,815 | Common | SHARED |
| 608550208 | MTEMEUR | MOLECULAR TEMPLATES INC | $600,574 | 0.02% | 522,238 | Common | SHARED |
| 04522R200 | — | ASLAN PHARMACEUTICALS LTD | $315,000 | 0.01% | 1,049,999 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.